GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
| Revenue (TTM) | $32.78B |
| Gross Profit (TTM) | $23.89B |
| EBITDA | $11.43B |
| Operating Margin | 36.30% |
| Return on Equity | 40.90% |
| Return on Assets | 10.00% |
| Revenue/Share (TTM) | $16.25 |
| Book Value | $11.86 |
| Price-to-Book | 4.56 |
| Price-to-Sales (TTM) | 3.26 |
| EV/Revenue | 2.925 |
| EV/EBITDA | 9.51 |
| Quarterly Earnings Growth (YoY) | 8.40% |
| Quarterly Revenue Growth (YoY) | 1.50% |
| Shares Outstanding | $2.00B |
| Float | $1.95B |
| % Insiders | 0.06% |
| % Institutions | 18.73% |
Volatility is currently expanding
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver.
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK's development and exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.iv
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca and Roche.
